KITE-718 / Gilead - LARVOL DELTA

Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells (clinicaltrials.gov) - P2 | N=700 | Enrolling by invitation | Sponsor: Kite, A Gilead Company | Trial completion date: Mar 2041 ➔ Dec 2040 | Trial primary completion date: Mar 2041 ➔ Dec 2040

Trial completion date • Trial primary completion date • Hematological Disorders • Hematological Malignancies • Oncology

KITE-718-301: Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers (clinicaltrials.gov) - P1 | N=16 | Terminated | Sponsor: Kite, A Gilead Company | Active, not recruiting ➔ Terminated; The study was terminated due to the sponsor's decision to discontinue the clinical trial.

Metastases • Trial termination • Multiple Myeloma • Oncology • HLA-DPB1

Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells (clinicaltrials.gov) - P2 | N=700 | Enrolling by invitation | Sponsor: Kite, A Gilead Company | Trial completion date: Nov 2026 ➔ Mar 2041 | Trial primary completion date: Nov 2026 ➔ Mar 2041

Trial completion date • Trial primary completion date • Hematological Disorders • Hematological Malignancies • Oncology

Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers (clinicaltrials.gov) - P1 | N=16 | Active, not recruiting | Sponsor: Kite, A Gilead Company | Trial completion date: Mar 2022 ➔ Oct 2022

Trial completion date • Multiple Myeloma • Oncology • Solid Tumor • HLA-DPB1

Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers (clinicaltrials.gov) - P1 | N=16 | Active, not recruiting | Sponsor: Kite, A Gilead Company | Trial completion date: Jan 2038 ➔ Mar 2022 | Trial primary completion date: Jan 2023 ➔ Jun 2021

Trial completion date • Trial primary completion date • Multiple Myeloma • Oncology • Solid Tumor

Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers (clinicaltrials.gov) - P1; N=16; Active, not recruiting; Sponsor: Kite, A Gilead Company; Recruiting ➔ Active, not recruiting; N=75 ➔ 16

Clinical • Enrollment change • Enrollment closed • Multiple Myeloma • Oncology • Solid Tumor • MRI

A phase 1 multicenter study evaluating the safety and efficacy of MHC class II-restricted MAGE-A3/A6 T-cell receptor engineered T cells (KITE-718) in patients with advanced cancers. (ASCO 2018) - P1; "After manufacturing, patients will receive cyclophosphamide and fludarabine conditioning chemotherapy followed by KITE-718 at a dose of 1 106 to 1 108 TCR-transduced T cells/kg. Patients amenable for loco-regional therapy or with history of stroke, myocardial infarction, or symptomatic deep vein thrombosis/pulmonary embolism are not eligible. The study is open and accruing patients."

Clinical • P1 data • Bladder Cancer • Melanoma • Non Small Cell Lung Cancer

Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers (clinicaltrials.gov) - P1; N=75; Recruiting; Sponsor: Kite, A Gilead Company; Trial completion date: May 2037 ➔ Jan 2038; Trial primary completion date: May 2022 ➔ Jan 2023

Clinical • Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology • Solid Tumor

Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers (clinicaltrials.gov) - P1; N=75; Recruiting; Sponsor: Kite, A Gilead Company; Trial completion date: Mar 2036 ➔ May 2037; Trial primary completion date: Jun 2021 ➔ May 2022

Clinical • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

KITE-718: Completion of P1a trial (NCT03139370) in MAGE A3/A6 solid tumors in Q4 2018 (Gilead) - Q4 FY2017 Results

Trial completion date • Oncology

KITE-718: Enrollment completion of P1a trial (NCT03139370) in MAGE A3/A6 solid tumors in H1 2020 (Gilead) - Q2 2019 Results

Enrollment status

KITE-718: Enrollment completion of P1a trial (NCT03139370) in MAGE A3/A6 solid tumors in H1 2020 (Gilead) - Q4 2018 Results

Enrollment status

Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers (clinicaltrials.gov) - P1; N=75; Recruiting; Sponsor: Kite, A Gilead Company; Trial completion date: Nov 2034 ➔ Mar 2036; Trial primary completion date: Aug 2020 ➔ Jun 2021

Clinical • Trial completion date • Trial primary completion date